secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250756
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio presents INB-619 preclinical data at ACR showing deep B cell depletion with minimal cytokine release
--------------------------------------------------------------------------------

- INB-619 achieved complete B cell depletion in SLE donor models, equivalent to FDA-approved blinatumomab and mosunetuzumab.
- INB-619 showed minimal IL-6 secretion at concentrations far lower than marketed TCEs, suggesting reduced CRS risk.
- INB-619 selectively expanded γδ T cells without activating αβ T cells, supporting a safer safety profile.
- Data presented at 2025 ACR Convergence; INB-619 is a potential first-in-class pan-γδ T cell engager targeting CD19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525250756/0001193125-25-250756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525250756/d65132d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer